Objective: To study collagen distribution and its quantitative variation in t he aortic adventitia of spontaneously hypertensive rats Methods: Sirus red stain was used to observe collagen distribution in aortic adventitia；Chloramine-T oxidation assay was employed to quantitate the collagen of aortic adventitia；Immuno-histochemical staining was adopted to detect type Ⅰ、Ⅲ collagen synthetic characteristic of vascular adventitial fibroblasts. Results: Collagen of rat aoritc wall mainly distributes in adventitia；SHR shows more collagen deposition in adventitia than WKY at the age of 8weeks and 24 weeks；The immuno-histochemical staining of type Ⅰ、Ⅲ collagen in vascular a dventitial fibroblasts is positive. Conclusions: All those results indicate that vascular adventitia ma y be involved in hypertensive vascular remodeling.and vascular adventitial fibroblasts can synthe size collagen type Ⅰ and Ⅲ.

0.05).CONCLUSION:Single oral dose of atenolol had no significant effect on the pharmacokinetics of nitrendipine.

AIM:Effects of anatotensin Ⅱ on type Ⅰ collagen synthesis and its mRNA expansion in cultured vascular adventitial fibroblasts. METHODS: Vascular adventitial fibroblasts (VAF)were isolated, cultured from rat thoracic aorta by explant method. ELISA was used to study type Ⅰ collagen synthesis and competihve RT - PCR was employed to detect its mRNA expression after angiotensin Ⅱ administration. RESULTS: Angiontensin Ⅱ caused a dose dependent increase of type Ⅰ collagen synthesis and its mRN expression in VAF. CONCLUSION: The results support that angiotensin Ⅱ is an important factor controlling collagen metabolism of VAF and VAF may play an im- portant role in vascular remodelling of hypertension.

Objective To detect and genotype the single-nucleotide polymorphisms (SNPs) in coding and promoter regions of human glucagon gene in Han Chinese residing in Shanghai and to analyse its association with essential hypertension (EH). Methods The identification of SNPs was performed by both direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC). For genotyping of SNPs direct sequencing was performed in 96 patients with EH and 96 normotensive controls (NT). Results Two SNPs in glucagon gene, one in the coding region (C3689T) and the other in the joint region, (G5505A) were found. A higher frequency SNP, C3689T, was genotyped and no significant difference in C3689T genotype frequency was found between EH and NT. Conclusion There is an important ethnic difference in SNP distribution of human glucagon gene. The distribution of C3689T genotype in Han Chinese is not different between EH and NT.

Aim To investigate the effects of angiotensin Ⅱ(AngⅡ),AT1 receptor antagonist losartan and AT2 receptor antagonist PD123177 on protein synthesis rate and AT1 receptor mRNA expression in cultured neonatal rat cardi ac myocytes. 　Methods The protein synthesis rate in cultured cardiac myocytes w as determined by the3H-leucine incorporation,AT1 receptor mRNA expressi on of cardiac myocytes was assessed by reverse transcription-polymerase chain reaction(RT-PCR). 　Results AngⅡ increased the 　3H-leucine incorporation in cultured cardiac myocytes in a dose dependent manner,losartan but not PD12317 7 could significantly inhibit AngⅡ induced protein synthesis,;AT1 receptor mRNA expression was upregulated after AngⅡ,and inhibited by losartan,but not PD123177. 　Conclusion AngⅡ can induce cardiac myocytes hypertrophy via upregulating AT1 receptor,and AT1 receptor antagonist can decrease AT1 rec eptor expression,reduce cardiac myocytes hypertrophy.

Objective To analysis the parameters of left ventricular hypertrophy(LVH) in patients with primary aldosteronism(PA).Methods Two hundred fifty patients were diagnosed as primary aldosteronsim in this study.One hundred fouty two PA patients undergone the adrenal venous sampling(AVS).Adenomas) APA) were diagnosed in 68 patients and idiopathic hyperaldosteronism(IHA) in 74 patients.During the same period, clinical characteristics and cardiovascular events of this group were compared with those of 246 patients with essential hypertension(EHT) randomly matched for age,gender,and systolic and diastolic blood pressure.Echocardiographic examinations and biochemical and hormonal assays were conducted in all subjects.Results 1) Left ventricular end-diastolic dimension(LVEDd) was increased in PA patients compared with values in EHT patients(PA;49.6?4.3 vs EHT:48.3?4.2 mm,P0.05);however,in grade 2 and 3 hypertension,the LVMI in patients with PA was increased compared with values in patients with EHT(P

18 years of age were enrolled. The blood pressure measurements at the wrist were compared with the results obtained by auscultatory measurement on left upper arm. Both measurements were taken 3 times in each person. A total 273 measurements were obtained in 91 participants. The evaluation of the accuracy was assessed by 2 statistical methods. (1)The differences between the 2 devices for a given measurement. (2) The differences between the 2 devices for a given person. Results Method 1 showed the sample mean errors and standard deviation of errors were 0.5?7.1 mm Hg for systolic blood pressure(SBP) and -1.6?6.1 mm Hg for diastolic blood pressure(DBP). Method 2 showed they were 0.5?6.1 mm Hg for SBP and -1.6?5.3 mm Hg for DBP. Blood pressure level and the wrist circumferences had no influence on the measurement errors. Conclusion The HEM-6000 wrist blood pressure device apparently met the AAMI criteria and is valid for patient self-measurement.

Objective To evaluate efficacy and safety of fixed combination of nitrendipine and atenolol in treatment for patients with mild to moderate essential hypertension and their optimal dosage matching.Methods Totally,275 patients with essential hypertension were selcted from seven hospitals in Shanghai,Nanjing and Suzhou,China and randomized into five groups with same proportional probability in a double-blind,double-dummy,parallel active-controlled,multi-center clinical trial,receiving fixed combination of nitrendipine and atenolol at three different dosage matching (nitrendipine/atenolol 5/12.5 mg,5/10 mg,5/7.5 mg for groups 1,2 and 3),and nitrendipine (10 mg for group 4) or atenolol (25 mg for group 5),respectively for eight weeks.Results Mean reduction of diastolic blood pressure (DBP)was (17±7) mm Hg,(18±9) mm Hg and (17±7) mm Hg for groupl,2 and 3,respectively from the baseline,significantly greater than that in groups 4 and 5[(13±7) mm Hg and (12±6) mm Hg,respectively].Mean reduction of systolic blood pressure (SBP) was (21 ±11)mm Hg,(24±12) mm Hg,(23±11) mm Hg,(19±13) mm Hg and (18±9) mm Hg,respectively for the five groups from the baseline,and the reduction in group 2 was significantly greater than that in group 5,with an overall efficacy of 94.4%,98.1% and 88.2% for groups 1,2 and 3,respectively,all statistically higher than that in group 5 (71.4%) with P＜0.01,eight weeks after treatment.The ratio of patients with increased dose of antihypertensive agents in week 5 was lower in group 2 than that in the other four groups,with mild adverse reaction only,no obvious change in laboratory biochemical examinations,and no needs in special management.Conclusions Fixed combination of atenolol and nitrendipine with an optimal doses of 5 mg and 10 mg respepctively was effective and safe for mild and moderate hypertension with good tolerance.

Objective To investigate the association between albuminuria incidence and blood pressure (BP) level or body weight index (BMI) in patients with essential hypertension from five regions in China. Methods A total of 5021 non-diabetic patients with clearly diagnosed essential hypertension were enrolled in our study. The participants came from five cities in China.Urinary albumin/creatinine ratio was measured in these patients for two times. The associations of albuminuria with BP level and BMI were analyzed. Results (1)There was no significant difference of albuminuria incidence between ＜60-year-old and ≥60-year-old patients. The longer the hypertension exited, the higher the albuminuria incidence was. (2) The albuminuria incidence was associated with blood pressure level significantly. The urinary protein excretion increased with the level of blood pressure. The albuminuria incidences in patients with normal BP, upper range of normal BP, Ⅰ , Ⅱ or Ⅲ stage hypertension were 26.3%, 27.3%, 28.7%, 31.5% and 40.3% respectively. (3) The albuminuria incidence was significantly different in patients with uncontrolled BP (≥ 140/90 mm Hg) compared with those with well controlled BP (＜ 140/90 mm Hg) (27.1% vs 30.2%, P＜0.05 ). (4) The albuminuria incidence was higher in obese patients compared with those with normal BMI at same BP level, but the difference was not statistically significant. (5) Patients with albuminuria had more cardiocerebral or renal events as compared to those without proteinuria. Conclusions The albuminuria incidence of non-diabetic hypertensive patients from 5 cities in China is 28.8%, of which the microalbuminuria incidence is 18.6% and the clinical albuminuria incidence is 10.2%. Uncontrolled BP is an important risk factor of proteinuria.

Objective To evaluate the efficacy and safety of domestic olmesartan in treatment of mild to moderate essential hypertension in comparison with losartan. Methods Two hundred and thirty-seven patients with mild to moderate essential hypertension were enrolled in a randomized, double-blind, multi-center, paralleded and active-controlled trial, and were divided into olmesartan group (olmesartan 20 mg + losartan 50 mg placebo) and losartan group (losartan 50 mg + olmesartan 20 mg placebo) for a 8-week therapy. Four weeks after treatment, dosages of drugs were doubled in patients with seated diastolic blood pressure ≥90 mmHg (1 mmHg =0.133 kPa). All patients were followed up every two weeks, and the efficacy and adverse effects were observed. Another 32 patients with mild to moderate essential hypertension were enrolled and given olmesartan only, and ambulatory blood pressure monitoring was performed before and 8 weeks after treatment. Results Compared with those before treatment, both systolic blood pressure and diastolic blood pressure significantly decreased in olmesartan group and losartan group 8 weeks after treatment [(15.2 ±13.3) mmHg and (19.5 ±11.8) mmHg, respectively for systolic blood pressure (P <0.001); (15.9 ±7.48) mmHg and (16.2 ± 5.95) mmHg, respectively for diastolic blood pressure (P < 0.01) ], while there was no significant difference between these two groups (P > 0.05). There was no significant difference in total effective rate and incidence of adverse effect between these two groups (86.9% vs 93.7% and 7.63% vs 5.88% , P > 0.05) . Ambulatory blood pressure monitoring demonstrated that trough to peak ratios of systolic blood pressure and diastolic blood pressure were 86% and 71%, respectively. Conclusion Domestic olmesaratan provides an effective, safe and long action in the treatment of mild to moderate essential hypertension.